US Brand Drug Prices Grew At Historically Low Rates In 2018 – IQVIA
Executive Summary
Net price growth of 0.3% for branded drugs in 2018 was 1.6% below Consumer Price Index inflation, while invoice prices grew an average of 5.5%.
You may also be interested in...
One More Score: CBO Projects HHS Rebate Proposal Would Boost Part D Spending $170bn
HHS downplays latest attempt to predict “complex behavior changes to a broken system.”
Industry's Drug Pricing Power Is Running On Fumes
Pharma is facing a big headwind in 2019 in the form of diminished drug pricing power. The pricing trend puts net drug prices squarely in the red for most large pharma manufacturers, but US lawmakers aren't likely to be reassured heading into an upcoming hearing on drug pricing.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.